Clinical responses (N=280)
| Response . | Patients with response, no. (%) . | ||
|---|---|---|---|
| Imatinib-resistant, n = 194 . | Imatinib-intolerant, n = 86 . | All patients, n = 280 . | |
| Complete hematologic response* | 92 (68)‡ | 45 (90)§ | 137 (74) |
| Cytogenetic response† | |||
| Major | 94 (48) | 40 (47) | 134 (48) |
| Complete | 58 (30) | 30 (35) | 88 (31)¶ |
| Partial | 36 (19) | 10 (12) | 46 (16)‖ |
| Minor | 16 (8) | 6 (7) | 22 (8) |
| Minimal | 25 (13) | 14 (16) | 39 (14) |
| Response . | Patients with response, no. (%) . | ||
|---|---|---|---|
| Imatinib-resistant, n = 194 . | Imatinib-intolerant, n = 86 . | All patients, n = 280 . | |
| Complete hematologic response* | 92 (68)‡ | 45 (90)§ | 137 (74) |
| Cytogenetic response† | |||
| Major | 94 (48) | 40 (47) | 134 (48) |
| Complete | 58 (30) | 30 (35) | 88 (31)¶ |
| Partial | 36 (19) | 10 (12) | 46 (16)‖ |
| Minor | 16 (8) | 6 (7) | 22 (8) |
| Minimal | 25 (13) | 14 (16) | 39 (14) |
Evaluation of CHR in patients without CHR at baseline.
Evaluation of cytogenetic response by FISH or cytogenetics (12 complete cytogenetic responders and 18 partial cytogenetic responders were assigned based on FISH). Patients were only considered a complete (partial) cytogenetic responder if they were more than 0% Ph+ (> 35% Ph+) at baseline.
(n=135)
(n=50)
In addition, 5 (2%) patients entered the study with a complete cytogenetic response and maintained their response in the study, and 3 (1%) patients had missing baseline assessment but complete cytogenetic response during the study.
In addition, 3 (1%) patients entered the study with a partial cytogenetic response and also maintained their response in the study.